Biomerica (BMRA) director Chin received 22,500 shares
Insider transactions reported
Eric Chin (director at Biomerica Inc., BMRA) reported that they received 22,500 shares on Dec 12, 2025. After these transactions the filing shows 32,500 shares held directly.
- Reporting person
- Chin Eric
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Dec 12, 2025 | Grant or award (A) | Common stock1 | +22,500 | - | - | 32,500 direct |
Holdings before and after
- Common stock: 10,000 to 32,500 direct
Footnotes from the filing
- 1. Award of restricted stock under the 2024 Stock Incentive Plan. The award of restricted stock will vest in full on the one-year anniversary of December 12, 2025, provided the reporting person remains in continuous service before the vesting date, subject to accelerated vesting in certain events, including upon certain changes of control of the Issuer.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Chin report in this BMRA Form 4?
Eric Chin (director at Biomerica Inc., BMRA) reported that they received 22,500 shares on Dec 12, 2025. After these transactions the filing shows 32,500 shares held directly.
How many BMRA shares does Chin hold after this filing?
The filing shows 32,500 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for BMRA
Across the 3 sessions after earlier BMRA headlines, the stock closed higher 2 times and lower 1 times, with a median move of 3.2% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BMRA | SPY |
|---|---|---|---|
| Dec 23, 2025 | Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test | +10.5% | +0.5% |
| Dec 11, 2025 | Egyptian Drug Authority Authorizes Biomerica's Complete Screening Test Portfolio | +3.2% | +0.2% |
| Nov 6, 2025 | Biomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand | -1.2% | -1.1% |
Earlier insider filings at BMRA
- Dec 31, 2025Chief Financial Officer Lu Gary was granted 40,000 shares, increasing direct ownership by 206% to 59,375 units (SEC Form 4)
- Dec 31, 2025Executive Vice-Chairman Barbieri Allen was granted 30,000 shares, increasing direct ownership by 127% to 53,543 units (SEC Form 4)
- Dec 31, 2025Director Gary M. Huff was granted 20,000 shares (SEC Form 4)
- Dec 31, 2025Chief Executive Officer Irani Zackary S. was granted 52,500 shares, increasing direct ownership by 33% to 211,320 units (SEC Form 4)
- Dec 31, 2025Director Moatazedi David was granted 20,000 shares, increasing direct ownership by 188% to 30,625 units (SEC Form 4)
Keep researching BMRA
- BMRA insider tradesEvery buy and sale reported by Biomerica Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- BMRA financial statementsRevenue, profit, cash flow and balance sheet from Biomerica Inc.'s SEC filings.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
Follow BMRA and get a push notification the moment its next story breaks.